News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Korea's Genexine Co. Ltd. Forms Clinical Research Collaboration With Merck & Co. (MRK)/MSD



11/11/2016 10:16:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Genexine of Korea entered a clinical research collaboration with Merck/MSD to test a two-drug combination as a treatment for HPV-induced cancer. The regimen will combine Genexine’s HPV therapeutic DNA vaccine and MSD’s PD-1 immunotherapy, Keytruda®. In a Phase I (solo) trial, the Genexine candidate, GX-188E, produced complete remissions of patients' CIN3 (cervical intraepithelial neoplasia) lesions in seven out of nine patients. Genexine did not disclose China plans for its drug, though the company usually out-licenses products to a domestic China pharma. Presently, neither the Genexine drug nor Keytruda is approved for China use.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES